Issue 2 Volume 15 (2026)

Autonomous experimental systems are progressing from isolated automation toward integrated platforms capable of proposing hypotheses, selecting tools, executing computational or physical procedures, interpreting observations, and modifying subsequent actions. In translational pharmacology, these capabilities create governance problems that cannot be resolved by model accuracy, conventional laboratory safety controls, general human oversight, or reporting requirements alone. This Original Autonom

---

Read More

Pharmaceutical translation is commonly described through development stages, publications, patents, candidate progression, or clinical milestones, yet these markers do not establish whether an originating laboratory claim has become reproducible, biologically relevant, manufacturable, pharmacologically credible, or meaningful for patients. This article develops an original Pharmaceutical Translation Observatory as a non-empirical evidence architecture for tracking these distinct transitions with

---

Read More

Next-generation pharmaceutical platforms can generate compounds, models, assays, manufacturing processes, and human-relevant experimental evidence with increasing speed and technical sophistication. Yet platform performance is frequently interpreted as evidence of translational maturity before product-specific quality, biological consequence, pharmacological behaviour, clinical utility, or implementation feasibility has been established. This article develops an original Translational Decision A

---

Read More

Biopharmaceutical manufacturing increasingly uses mechanistic models, statistical predictors, process analytical technologies, metabolic reconstructions, and digital-twin concepts to anticipate culture behavior and product quality. However, an accurate predictor of a selected process variable is not necessarily a model of the evolving manufacturing system. It may lack a persistent representation of cell state, explicit intervention semantics, multiscale temporal dynamics, calibrated uncertainty,

---

Read More

Pharmacovigilance systems operate within changing medicinal-product, population, data, analytical, and organizational environments. Static surveillance configurations may consequently become misaligned with the products being monitored, the populations exposed, the information captured, or the decisions supported. This article develops an original adaptive-governance framework for pharmacovigilance under model drift, product evolution, data-source change, and emerging patterns of medicine use. T

---

Read More

Precision pharmacotherapy requires decisions about what dose should be administered next, not merely forecasts of what is likely to occur under previously observed treatment patterns. Current patient models can integrate pharmacokinetic, pharmacodynamic, laboratory, physiological, and treatment data, yet their predictions may remain associational when treatment is repeatedly adapted in response to evolving patient states. Delayed efficacy and toxicity, incomplete clinical observation, treatment-

---

Read More

Artificial intelligence is increasingly used to predict pharmacokinetic parameters, characterize exposure–response relationships, select population models, interpret therapeutic drug-monitoring data, and support individualized dosing. However, analytical performance alone does not explain why apparently similar systems succeed in one setting, fail in another, or create unintended clinical consequences. This realist review examines how data, model, patient, organizational, and decision contexts i

---

Read More

Clinical pharmacokinetic and pharmacodynamic modelling supports the interpretation of dose, exposure, biological response, and patient variability, but most models remain tied to a particular drug, population, sampling design, endpoint, or clinical task. This task-specific orientation limits reuse across evolving treatment contexts and does not inherently address informative observation processes, distribution shift, or uncertainty under transfer. This Original Foundation-Model Architecture Arti

---

Read More

Biomanufacturing cells are increasingly engineered with synthetic regulatory circuits, dynamic metabolic controls, automated design workflows, and process-aware sensing. Nevertheless, individual engineering improvements do not by themselves create manufacturing systems capable of coordinating metabolic state, recombinant-protein processing, product quality, productivity, and robustness across scales. This article proposes an evidence-bounded programmable biomanufacturing-cell architecture as an

---

Read More

Medicine-safety evidence is distributed across spontaneous case reports, clinical records, registries, observational studies, scientific publications, regulatory assessments, product labels, and manufacturing or product histories. These sources differ in structure, terminology, provenance, temporal coverage, jurisdiction, and evidentiary meaning, limiting the reconstruction of how an emerging concern develops into a safety signal, causal assessment, regulatory response, or product change. This o

---

Read More

Cell-dependent biomanufacturing has enabled diverse therapeutic products, yet its reliance on living production hosts can constrain rapid process reconfiguration, local production, and transfer across therapeutic modalities. Cell-free pharmaceutical biotechnology removes the requirement to maintain an intact production cell, but current evidence remains fragmented across reaction engineering, template design, post-translational processing, purification, stabilization, and distributed implementat

---

Read More